XKRX290650
Market cap344mUSD
Dec 26, Last price
22,250.00KRW
1D
-1.33%
1Q
12.09%
IPO
143.61%
Name
L&C Bio Co Ltd
Chart & Performance
P/E
10.44
P/S
7.33
EPS
2,131.86
Div Yield, %
0.22%
Shrs. gr., 5y
5.17%
Rev. gr., 5y
26.52%
Revenues
68.87b
+31.00%
Net income
48.36b
+964.24%
CFO
-12.13b
L+99.69%
Dividend
Dec 27, 2023100 KRW/sh
Profile
L&C BIO Co., Ltd. operates as a research and development company in tissue regeneration medicine. It offers human tissue, medical device, and cosmetics products. The company was founded in 2011 and is headquartered in Seongnam, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 68,869,546 31.00% | 52,572,492 15.10% | 45,677,014 38.53% | ||||||
Cost of revenue | 54,464,918 | 37,196,504 | 28,076,086 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 14,404,628 | 15,375,988 | 17,600,927 | ||||||
NOPBT Margin | 20.92% | 29.25% | 38.53% | ||||||
Operating Taxes | 14,406,644 | (1,128,659) | 1,514,818 | ||||||
Tax Rate | 100.01% | 8.61% | |||||||
NOPAT | (2,016) | 16,504,647 | 16,086,109 | ||||||
Net income | 48,361,015 964.24% | 4,544,175 -67.11% | 13,814,433 27.76% | ||||||
Dividends | (1,114,923) | (1,114,923) | (1,077,665) | ||||||
Dividend yield | 0.16% | 0.21% | 0.13% | ||||||
Proceeds from repurchase of equity | (840,000) | (2,711,457) | |||||||
BB yield | 0.12% | 0.33% | |||||||
| Debt | |||||||||
Debt current | 80,716,755 | 10,641,266 | 732,762 | ||||||
Long-term debt | 3,689,939 | 73,008,551 | 7,358,311 | ||||||
Deferred revenue | 10 | 1,270,939 | 1,208,240 | ||||||
Other long-term liabilities | 2,118,761 | (40) | (300) | ||||||
Net debt | (23,616,890) | (5,253,024) | (50,463,901) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (12,132,875) | (6,075,796) | 10,906,636 | ||||||
CAPEX | (24,502,960) | (37,703,137) | (11,427,781) | ||||||
Cash from investing activities | 24,634,288 | (83,632,541) | (20,488,281) | ||||||
Cash from financing activities | (4,155,265) | 78,927,600 | 4,697,449 | ||||||
FCF | (42,135,080) | (39,402,647) | (438,825) | ||||||
| Balance | |||||||||
Cash | 59,192,647 | 12,316,496 | 19,620,050 | ||||||
Long term investments | 48,830,938 | 76,586,345 | 38,934,924 | ||||||
Excess cash | 104,580,107 | 86,274,216 | 56,271,124 | ||||||
Stockholders' equity | 114,443,754 | 107,028,373 | 101,880,426 | ||||||
Invested Capital | 136,528,368 | 94,134,214 | 36,088,723 | ||||||
ROIC | 25.35% | 51.78% | |||||||
ROCE | 5.97% | 8.06% | 17.29% | ||||||
| EV | |||||||||
Common stock shares outstanding | 24,722 | 22,685 | 22,298 | ||||||
Price | 29,000.00 25.54% | 23,100.00 -36.89% | 36,600.00 6.09% | ||||||
Market cap | 716,945,018 36.82% | 524,020,982 -35.79% | 816,090,330 8.03% | ||||||
EV | 710,536,548 | 528,637,111 | 773,871,219 | ||||||
EBITDA | 20,059,040 | 19,883,740 | 20,502,874 | ||||||
EV/EBITDA | 35.42 | 26.59 | 37.74 | ||||||
Interest | 6,191,078 | 3,076,147 | 460,266 | ||||||
Interest/NOPBT | 42.98% | 20.01% | 2.62% | ||||||